Nivolumab reduces symptoms in relapsed metastatic head and neck cancer

(European Society for Medical Oncology) Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Congress in Copenhagen1 and published in the New England Journal of Medicine.